| Drug Name: | Hydroxyurea (127-07-1) |
|---|---|
| PubChem ID: | 3657 |
| SMILES: | C(=O)(N)NO |
| InchiKey: | VSNHCAURESNICA-UHFFFAOYSA-N |
| Therapeutic Category: | Antineoplastic Agents, Antisickling Agents, Enzyme Inhibitors, Hematologic Agents, Nucleic Acid Synthesis Inhibitors |
| Molecular Weight (dalton) | : | 76.055 |
| LogP | : | -0.9561 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 75.35 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Abnormality Of Hepatomegaly | BCR-ABL (b3a2) (P00004) | The administration of hydroxyurea was associated with characteristic t(9;22)(q34;q11) chromosomal translocation and the bcr-abl (b3a2) DNA fusion,which lead to thalassaemia major. [ ADR Type 3 ] | Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelid |
| Myeloid Leukaemia | BCR-ABL (b3a2) (P00004) | The administration of hydroxyurea was associated with characteristic t(9;22)(q34;q11) chromosomal translocation and the bcr-abl (b3a2) DNA fusion,which leads to chronic myeloid leukaemia (CML) [ ADR Type 3 ] | Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelid |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category